Dr Lan Gao

Effects and costs of real-time cardiac telerehabilitation: randomised controlled non-inferiority trial

Ralph Maddison, Jonathan Rawstorn, Ralph Stewart, Jocelyne Benatar, Robyn Whittaker, Anna Rolleston, Yannan Jiang, Lan Gao, Marj Moodie, Ian Warren, Andrew Meads, Nicholas Gant

(2019), Vol. 105, pp. 122-129, Heart, London, Eng., C1

Modelled economic evaluation of Nivolumab for the treatment of second-line advanced or metastatic squamous non-small-cell lung cancer in Australia using both partition survival and Markov models

Lan Gao, Shu-Chuen Li

(2019), Vol. 17, pp. 371-380, Applied health economics and health policy, Cham, Switzerland, C1

Measuring subjective wellbeing in patients with heart disease: relationship and comparison between health-related quality of life instruments

Lan Gao, Marj Moodie, Gang Chen

(2019), Vol. 28, pp. 1017-1028, Quality of life research, Dordrecht, The Netherlands, C1

Utility-weighted modified Rankin Scale: still too crude to be a truly patient-centric primary outcome measure?

Venesha Rethnam, Julie Bernhardt, Helen Dewey, Marj Moodie, Hannah Johns, Lan Gao, Janice Collier, Fiona Ellery, Leonid Churilov, AVERT Trial Collaboration Group

(2019), pp. 1-10, International journal of stroke, London, Eng., C1

Are office-based workplace interventions designed to reduce sitting time cost-effective primary prevention measures for cardiovascular disease? A systematic review and modelled economic evaluation

Lan Gao, Phuong Nguyen, David Dunstan, Marjory Moodie

(2019), Vol. 16, International journal of environmental research and public health, Basel, Switzerland, C1

Economic evaluation of a phase III international randomised controlled trial of very early mobilisation after stroke (AVERT)

Lan Gao, Lauren Sheppard, Olivia Wu, Leonid Churilov, Mohammadreza Mohebbi, Janice Collier, Julie Bernhardt, Fiona Ellery, Helen Dewey, Marj Moodie, AVERT Trial Collaboration Group

(2019), Vol. 9, BMJ open, London, Eng., C1

Within trial cost-utility analysis of disease management program for patients hospitalized with atrial fibrillation: results from the SAFETY trial

J Byrnes, J Ball, L Gao, Y Kai Chan, S Kularatna, S Stewart, P Scuffham

(2019), pp. 1-8, Journal of medical economics, Abingdon, Eng., C1

The cost-effectiveness of omega-3 polyunsaturated fatty acids - the Australian healthcare perspective

L Gao, M Moodie, S Li

(2019), pp. 1-7, European journal of internal medicine, Amsterdam, The Netherlands, C1

Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure

L Gao, M Moodie

(2019), Vol. 9, pp. 1-9, BMJ Open, London, Eng., C1

Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation

Lan Gao, Shu-Chuen Li

(2018), Vol. 25, pp. 671-680, Breast cancer, Berlin, Germany, C1

Economic evaluation of a randomized controlled trial of an intervention to reduce office workers' sitting time: the 'Stand Up Victoria' trial

Lan Gao, Anna Flego, David Dunstan, Elisabeth Winkler, Genevieve Healy, Elizabeth Eakin, Lisa Willenberg, Neville Owen, Anthony LaMontagne, Anita Lal, Glen Wiesner, Nyssa Hadgraft, Marj Moodie

(2018), Vol. 44, pp. 503-511, Scandinavian journal of work, environment and health, Helsinki, Finland, C1

Cost-effectiveness of a lifestyle modification program in long-term survivors of hemopoietic stem cell transplantation

L Gao, M Moodie, V Brown, S Avery

(2017), Vol. 31, pp. 1-10, Clinical transplantation, Chichester, Eng., C1

The cost-effectiveness of the online MindSpot Clinic for the treatment of depression and anxiety in Australia

Y-C Lee, L Gao, B Dear, N Titov, C Mihalopoulos

(2017), Vol. 20, pp. 155-166, Journal of mental health policy and economics, Milano, Italy, C1

Can the direct medical cost of chronic disease be transferred across different countries? Using cost-of-illness studies on type 2 diabetes, epilepsy and schizophrenia as examples

L Gao, H Hu, F-L Zhao, S-C Li

(2016), Vol. 11, pp. 1-17, PLoS one, San Francisco, Calif., C1

Emerging drugs for partial-onset epilepsy: a review of brivaracetam

L Gao, S Li

(2016), Vol. 12, pp. 719-734, Therapeutics and clinical risk management, Macclesfield, Eng., C1

Scaling-up an efficacious school-based physical activity intervention: study protocol for the 'Internet-based professional learning to help teachers support activity in youth' (iPLAY) cluster randomized controlled trial and scale-up implementation evaluation

C Lonsdale, T Sanders, K Cohen, P Parker, M Noetel, T Hartwig, D Vasoncellos, M Kirwan, P Morgan, J Salmon, M Moodie, H McKay, A Bennie, R Plotnikoff, R Cinelli, D Greene, L Peralta, D Cliff, G Kolt, J Gore, L Gao, D Lubans

(2016), Vol. 16, pp. 1-16, BMC public health, London, Eng., C1

Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy

L Gao, L Xia, S Pan, T Xiong, S Li

(2015), Vol. 110, pp. 146-156, Epilepsy research, Amsterdam, The Netherlands, C1-1

Efficacy and safety of thrombin-receptor antagonist (atopaxar and vorapaxar) in patients with acute coronary syndrome or coronary artery disease-a meta-analysis of randomized controlled trials

L Gao, F Zhao, S Li

(2015), pp. 22-32, Value in health regional issues, Amsterdam, The Netherlands, C1

Health-related quality of life and willingness to pay per quality-adjusted life-Year threshold-A study in patients with epilepsy in China

L Gao, L Xia, S-Q Pan, T Xiong, S-C Li

(2015), Vol. 6, pp. 89-97, Value in health regional issues, Amsterdam, The Netherlands, C1-1

Adding a new anticoagulant or antiplatelet agent for patient receiving aspirin after an acute coronary syndrome? - Results from a pairwise and network meta-analysis of randomized-controlled trials

L Gao, S-C Li

(2014), Vol. 6, pp. 173-199, British journal of medicine and medical research, West Bengal, India, C1

Psychometric properties of Chinese language Liverpool Seizure Severity Scale 2.0 (LSSS 2.0) and status and determinants of seizure severity for patients with epilepsy in China

L Gao, L Xia, S-Q Pan, T Xiong, S-C Li

(2014), Vol. 31, pp. 187-193, Epilepsy & Behavior, Amsterdam, The Netherlands, C1-1

Validation of the Chinese version of the NUCOG cognitive screening tool in patients with epilepsy, dementia and other neurological disorders

L Gao, S-C Li, L Xia, S Pan, D Velakoulis, M Walterfang

(2014), Vol. 21, pp. 980-987, Journal of clinical neuroscience, Amsterdam, The Netherlands, C1-1

Reliability and validity of QOLIE-10 in measuring health-related quality of life (HRQoL) in Chinese epilepsy patients

L Gao, L Xia, S-Q Pan, T Xiong, S-C Li

(2014), Vol. 108, pp. 565-575, Epilepsy research, Amsterdam, The Netherlands, C1-1

Validation of a Chinese version of the Quality of Well-Being Scale-Self-Administered (QWB-SA) in patients with epilepsy

L Gao, L Xia, S-Q Pan, T Xiong, S-C Li

(2013), Vol. 54, pp. 1647-1657, Epilepsia, Hoboken, N.J., C1-1

Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials

L Gao, L Xia, F-L Zhao, S-C Li

(2013), Vol. 103, pp. 31-44, Epilepsy research, Amsterdam, The Netherlands, C1-1

Burden of disease studies in the asia-pacific region: are there enough being performed to provide information for evidence-based health policy?

F Zhao, L Gao, S Li

(2013), Vol. 2, pp. 152-159, Value in health regional issues, Amsterdam, The Netherlands, C1-1

Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials

L Gao, F-L Zhao, S-C Li

(2012), Vol. 120, pp. 367-375, Experimental and clinical endocrinology & diabetes, Stuttgart, Germany, C1-1

Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China

L Gao, F-L Zhao, S-C Li

(2012), Vol. 28, pp. 436-444, International journal of technology assessment in health care, Cambridge, Eng., C1-1